CVKD advances cardiovascular therapeutics, acquiring Factor XIa assets; tecarfarin progresses toward pivotal trials. Low float, $45/$30 targets highlight potential catalysts.
Cadrenal Therapeutics acquired eXIthera’s Factor XIa inhibitors, expanding its anticoagulation pipeline with Phase 2-ready assets and reinforcing leadership in cardiovascular therapeutics.
Cadrenal Therapeutics has acquired eXIthera Pharmaceuticals’ portfolio of Factor XIa inhibitors to expand its offerings in the anticoagulation market.
Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings
*Sponsored
July 15, 2026
Greetings Readers,
A dynamic force in the cardiovascular treatment space has recently made a strategic acquisition that’s turning heads across the biopharma community.
This move strengthens its position in addressing some of the most pressing unmet needs in heart health, expanding both research depth and therapeutic reach.
With a focus on advancing late-stage clinical programs and accelerating timelines, the company is clearly stepping into a new phase of momentum.
For those watching the intersection of innovation and patient care, this latest development signals something significant worth a closer look, and a deeper appreciation for what’s quietly taking shape in the field of cardiovascular medicine.
Now, mix in a low float of fewer than 2Mn shares and a pair of analyst targets suggesting SIGNIFICANT upside potential, and there's no doubt why this Nasdaq profile just rocketed up my watchlist.
Drop what you're doing and consider this under-the-radar idea for your radar:
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics for patients with cardiovascular disease.
Cadrenal’s lead investigational product is tecarfarin, a novel oral vitamin K antagonist anticoagulant that addresses unmet needs in anticoagulation therapy.
Tecarfarin is a reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.
And based on several potential breakout catalysts, (Nasdaq: CVKD) has found its way to the top of my watchlist. Check them out:
But more on those in a second...
Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an investigational anticoagulant designed as a superior and safer Vitamin K antagonist (VKA) for patients with implanted cardiac devices or rare cardiovascular conditions.
The company strives to improve patient outcomes and reduce major adverse events among these populations, who currently lack any approved chronic anticoagulation options besides warfarin, a medication known for its serious side effects and complex management requirements.
Through its innovative approach, Cadrenal aims to alleviate some of the most significant challenges faced by patients and healthcare providers who rely on warfarin.
Cadrenal’s Phase 3-ready drug candidate, tecarfarin, represents a novel VKA anticoagulant supported by extensive data suggesting its potential to be superior to warfarin, with the possibility of fewer adverse events such as strokes, heart attacks, bleeding, and death.
Tecarfarin has received orphan drug designation for heart failure patients with left ventricular assist devices (LVADs), as well as both orphan drug and fast track status for end-stage kidney disease (ESKD) patients with atrial fibrillation (Afib).
The company is actively pursuing pivotal clinical trials and exploring clinical and commercial partnership opp's.
Cadrenal also plans to investigate tecarfarin in patients with mechanical heart valves who experience anticoagulation difficulties due to genetic warfarin resistance, polypharmacy, or kidney impairment.
Tecarfarin is metabolized through a different pathway than warfarin, and data indicate that its efficacy remains unaffected by common drug-drug interactions or kidney impairment, challenges that are prevalent among these patient populations.
Phase 2/3 clinical trials have demonstrated that tecarfarin may offer greater stability and increased time in therapeutic range, which is inversely correlated with major adverse events.
As the only new VKA blood thinner in development specifically for warfarin-dependent patients with implanted cardiac devices or rare cardiovascular conditions, Cadrenal is boldly challenging the status quo, seeking to innovate a new anticoagulant that delivers better care to underserved patients.


Grab Sources Here: CVKD Website.
Factor XI plays only a minor role in normal clotting but is a major driver of pathological thrombosis. By selectively targeting FXIa, Frunexian and EP-7327 could deliver potent antithrombotic effects without dramatically increasing bleeding risk.
This is why Factor XIa inhibitors have become one of the hottest areas of cardiovascular drug development. Big pharma has committed billions of dollars to acquire or license programs in this space, validating the opportunity Cadrenal now controls.
And as I mentioned earlier, (Nasdaq: CVKD) has several potential catalysts to consider immediately. Check them out:
According to info from the Yahoo Finance website, CKVD has a very low float..
The website reports this profile to have roughly 1.50Mn shares in its float.
Why is that important? It's important on one crucial level. Volatility potential.
If positive company news appears towards the end of 2025, could it provide a breakout spark when paired with this volatile potential?
Last month, Noble Capital Markets analyst, Robert LeBoyer, reiterated his $45 price target.
From Friday's 4:00PM EST closing valuation, that target provides CVKD with a potential upside of 225+%!
Details from the report:
Conclusion. The product acquisition builds the pipeline and adds products with a different mechanism of action for complementary indications. A clinical study testing tecarfarin in patients during the high-risk period after starting renal dialysis is planned for later this year, with a study in mechanical ventricular assist devices planned for FY2026. We reiterate our Outperform rating and $45 price target.
Another analyst, David Bautz of Zacks Small-Cap Research, reiterated their $30 target for CVKD this summer.
From its 4:00PM EST close on Friday, that targets suggests 120+% potential upside for CVKD.
Report highlights:
We look forward to additional updates from the company regarding the upcoming Phase 3 trial of tecarfarin in LVAD patients. Having Abbott as a partner for the Phase 3 trial is a tremendous opp. for the company as Abbott has extensive experience working with LVAD patients and conducting successful trials with that population. With no changes to our model our valuation remains at $30 per share.
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settings
Company is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk
PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of the assets of eXIthera Pharmaceuticals (“eXIthera”), including its proprietary portfolio of investigational intravenous (IV) and oral Factor XIa inhibitors. The acquisition significantly enhances Cadrenal’s pipeline, adding drug candidates that address large and underserved segments of the current $38Bn global anticoagulation market.
eXIthera’s lead asset, frunexian, is a first-in-class, Phase 2-ready intravenous (IV) Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices plays a significant role, such as cardiopulmonary bypass, catheter thrombosis, and other blood-contacting implanted cardiac devices. The acquisition also includes EP-7327, an oral Factor XIa inhibitor, for the prevention and treatment of major thrombotic conditions.
“With this acquisition, Cadrenal is the only company in the world developing a novel vitamin K antagonist (tecarfarin) and Factor XIa inhibitors, a promising new class of anticoagulants,” said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. “These newly acquired assets will expand Cadrenal’s capabilities in an effort to address even more critical gaps in current antithrombotic treatment, especially for patients for whom current therapies are unreliable or carry excessive bleeding risk.”
“This acquisition reinforces Cadrenal’s long-term vision of becoming a category leader in anticoagulation,” added Pham. “With tecarfarin planning a trial in patients with end-stage kidney disease transitioning to dialysis, our plans for LVAD patients, and the current addition of frunexian and EP-7327, we believe that Cadrenal is strategically positioned to deliver differentiated therapeutics across the entire spectrum of patients with cardiovascular thrombotic risk.”
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis
Advances knowledge about the use of tecarfarin in patients with severe kidney impairment, including dialysis
Pivotal step forward in pursuit of ESKD + Atrial Fibrillation (AFib) registration trial Addresses a critical current treatment gap in patients with ESKD
PONTE VEDRA, Fla., August 05, 2025, (BUSINESS WIRE), Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing transformative therapeutics that specifically address limitations of current anticoagulation therapy, today announced clinical trial initiation plans for its lead late-stage drug candidate, tecarfarin, in patients with ESKD who are transitioning to dialysis. Enrollment is planned to begin later this year and will include patients with and without atrial fibrillation (AFib).
Patients with severe kidney disease are already at high risk for thrombotic cardiovascular events such as myocardial infarction and stroke, along with a much greater risk of AFib and venous thromboembolism compared to subjects with normal kidney function. When ESKD patients require dialysis, their transition period comes with even greater risk of myocardial infarction, stroke, and a substantial increase in mortality.
"There is a critical need for safe, effective anticoagulants for use in ESKD patients," said Quang X. Pham, Chairman and CEO of Cadrenal Therapeutics. "Tecarfarin’s orphan drug and fast-track designations in ESKD patients with AFib underscore this need, and we are excited to advance this program. This study will be an important step forward for the continued development of tecarfarin in ESKD and in other areas with real opp's to improve patient outcomes with a potentially better vitamin K antagonist."
Now initiated: coverage is officially a "go" on Cadrenal Therapeutics, Inc. (Nasdaq: CVKD).
When updates are available, I'll get them out to you quickly. Talk soon.
Sincerely,
TopStocks
NASDAQ: CVKD
25.95M
-8.88
February 26, 2026